The tiny pacemaker smaller than a grain of rice that could revolutionise heart surgery
Pacemakers use electric pulses to steady heartbeats and protect the organ against potentially fatal abnormal rhythms.
The small device is typically about the size of a matchbox and weighs about 20 to 50g. It consists of a pulse generator, which has a battery and a tiny computer circuit, and one or more wires known as pacing leads, which attach to your heart.
But at just 1.8mm wide, 3.5mm long and 1mm thick, researchers at Northwestern University in Illinois, US, have developed one that is smaller than a grain of rice.
The pacemaker has no wires and does not need to be removed at a later date because it dissolves.
A study published in the journal Nature found the miniature pacemaker worked well in mice and rats and successfully corrected abnormalities in heart rhythm.
Scientists came up with the invention while searching for a way to monitor the hearts of babies who had undergone life-saving cardiac surgery.
'Our major motivation was children,' cardiologist Igor Efimov, who co-authored the study, told science publication IBSA Foundation.
'About 1 per cent of children are born with congenital heart defects, [and often] in about seven days or so [of temporary stimulation], most patients' hearts will self-repair. But those seven days are absolutely critical.'
Affecting one in 100 babies born in the UK, those with a congenital heart defect may need surgery before being fitted with a temporary pacemaker to monitor heart rhythm. It is then removed again at a later date.
But surgery is risky and can lead to infection, lacerations and perforations.
However, with this new pacemaker, the risk of life-threatening complications is reduced because it is small enough to fit into a syringe and can be inserted without the need for surgery.
The mini pacemaker is made with two electrodes of different metals, which, when in contact with the body's fluids, generate an electrical current capable of stimulating the heart when needed.
Its soft and flexible structure also means it can fit onto the heart wall without the need for invasive stitches.
Researchers hope the device will open up new possibilities for cardiologists, including being able to give patients several pacemakers at once, enabling them to control single areas of the heart.
However, these small pacemakers are not intended to replace permanent ones in patients with chronic heart rhythm problems who need them for life.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
6 hours ago
- The Independent
‘Game-changing' new Alzheimer's drug could slow progression of disease
An Alzheimer's drug that clears away plaque build-up in the brain could slow progression of the disease and delay the onset of symptoms, early trials have shown. There is currently no cure for the disease, which can severely affect memory and impact people's ability to carry out daily tasks, and the medicines available can only reduce symptoms. But a new drug called Trontinemab is showing promising results, the Alzheimer's Association International Conference in Toronto was told. The drug has been tested on a small number of patients, but 49 out of 54 with early-stage Alzheimer's showed signs of improvement within 28 weeks during a trial, according to Roche, the pharmaceutical company behind the drug. Researchers said 91 per cent of the participants showed a reduction in clusters of protein on their brains, known as amyloid plaques – a key marker of Alzheimer's. Alzheimer's is thought to be caused by an abnormal build-up of this protein around brain cells, while another protein called tau forms tangles within brain cells. These can interrupt the chemical messengers responsible for sending signals between brain cells, according to the NHS. The new drug was found to reduce amyloid proteins to a level so low that scan results on patients taking it for seven months were considered to be 'amyloid negative'. It is thought that the clearance of plaques slows down the progression of the disease and delays the onset of symptoms. 'Alzheimer's disease represents one of the greatest challenges in healthcare today, and tackling it requires early detection and effective therapeutics,' Dr Levi Garraway, chief medical officer of Roche, said. He added: 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention.' Professor Sir John Hardy, the chairman of molecular biology of neurological disease at University College London's Institute of Neurology, who was not involved in the trial, told The Telegraph the drug was a 'massive improvement' and works faster than other Alzheimer's drugs on the market. 'There is no doubt this could be game-changing. We hope that if we can use these drugs to people early, we can halt the progression of disease, even before people have symptoms. Now we need to see the size of the clinical effect,' he said. However, the drug does have some side effects, with five participants of 149 (3 per cent) suffering from lesions or swelling in their brains after taking it. But all the participants recovered, and it was considered to be safer than other Alzheimer's drugs that have resulted in 17 per cent of participants experiencing similar side effects. The final part of the trial, which will test the drug on a large number of patients, is yet to be carried out. But if it is successful, health bodies in the UK will need to decide whether it is cost-effective enough to use on the NHS. An estimated 982,000 people are living with some form of dementia, including Alzheimer's, in the UK, with the disease most common in people over the age of 65. But more than a third of people with the condition do not have a diagnosis. The number of those with the disease is expected to rise to 1.4 million by 2040, according to the Alzheimer's Society.
The National
7 hours ago
- The National
Death toll in Palestine surpasses 60,000, health ministry reports
The ministry has said the death toll has climbed to to 60,034, with another 145,870 people wounded since Hamas invaded Israel on October 7, 2023. Women and children are believed to make up half the death toll. The United Nations and other independent experts view the health ministry's figures as the most reliable count of casualties. Israel's assault on Gaza has destroyed vast areas of the region and displaced around 90% of the population. READ MORE: Labour minister clashes with BBC presenter over Gaza The war took a major turn in early March when Israel imposed a complete two-and-a-half month blockade, barring the entry of all food, medicine, fuel and other goods. Israel eased those restrictions in May but also pushed ahead with a new US-backed aid delivery system that has been wracked by chaos and violence. The leading international authority on food crises, The Integrated Food Security Phase Classification (IPC), has said the 'worst-case scenario of famine is currently playing out in the Gaza Strip'. International pressure led Israel over the weekend to announce measures, including daily humanitarian pauses in fighting in parts of Gaza and air drops. The United Nations and Palestinians on the ground say little has changed though, and desperate crowds continue to overwhelm and unload delivery trucks before they can reach their destinations. IPC said Gaza has teetered on the brink of famine for two years but recent developments have 'dramatically worsened' the situation, including 'increasingly stringent blockades' by Israel. A formal famine declaration, which is rare, requires the kind of data that the lack of access to Gaza and mobility within has largely denied. The IPC has only declared famine a few times — in Somalia in 2011, South Sudan in 2017 and 2020, and parts of Sudan's western Darfur region last year. READ MORE: John Swinney to call for 'immediate' constitutional convention on independence But independent experts say they do not need a formal declaration to know what they are seeing in Gaza. 'Just as a family physician can often diagnose a patient she's familiar with based on visible symptoms without having to send samples to the lab and wait for results, so too we can interpret Gaza's symptoms. This is famine,' Alex de Waal, author of Mass Starvation: The History And Future Of Famine and executive director of the World Peace Foundation, told The Associated Press. The report is based on available information through to July 25 and says the crisis has reached 'an alarming and deadly turning point'. It says data indicates that famine thresholds have been reached for food consumption in most of Gaza — at its lowest level since the war began — and for acute malnutrition in Gaza City. The report says nearly 17 out of every 100 children under the age of five in Gaza City are acutely malnourished. The IPC's latest analysis in May warned that Gaza will likely fall into famine if Israel does not lift its blockade and stop its military campaign. Its new alert calls for immediate and large-scale action and warns: 'Failure to act now will result in widespread death in much of the strip.'
The Independent
7 hours ago
- The Independent
Cancer drug demand drives higher sales for AstraZeneca
AstraZeneca has announced a jump in sales in recent months after a surge in demand for cancer drugs, as the pharmaceutical giant prepares to plug 50 billion dollars (£37 billion) into its US expansion. The drug-maker reported total revenues of 28 billion US dollars (£21 billion) for the first half of 2025. This is 11% higher, at constant exchange rates, than the same period a year ago. AstraZeneca said the uplift was largely driven by its oncology medicines, with product sales surging by 16% year on year, thanks to growth in demand for drugs including Tagrisso and Imfinzi. Revenues from oncology products, which refer to the diagnosis and treatment of cancer, made up 43% of the company's total sales. The group's pre-tax profit soared by 27% to 6.5 billion US dollars (£4.9 billion) for the first half, compared with last year. AstraZeneca, which is based in the UK, last week pledged a mammoth investment into the US over the next five years, where it generates the highest proportion of sales. The money will fund a new multibillion dollar manufacturing facility in Virginia, to be the firm's largest single manufacturing investment in the world. The new factory will produce drug substances for its growing weight management and metabolic portfolio, including oral GLP-1 products. GLP-1 is the scientific term for weight-loss medication, which works by reducing food cravings. Oral medicines can be taken in tablet form, while other drugs are taken as injections. 'Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent,' Pascal Soriot, AstraZeneca's chief executive, said. 'This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver 80 billion dollars revenue by 2030.'
